Alexandria Capital LLC boosted its position in shares of Edwards Lifesciences Corporation (NYSE:EW) by 1.7% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 1,146 shares of the medical research company’s stock after buying an additional 19 shares during the period. Alexandria Capital LLC’s holdings in Edwards Lifesciences Corporation were worth $136,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. FineMark National Bank & Trust boosted its stake in shares of Edwards Lifesciences Corporation by 1.7% in the second quarter. FineMark National Bank & Trust now owns 26,833 shares of the medical research company’s stock valued at $3,173,000 after buying an additional 441 shares during the last quarter. Cornerstone Advisors Inc. increased its stake in Edwards Lifesciences Corporation by 25.1% in the second quarter. Cornerstone Advisors Inc. now owns 1,092 shares of the medical research company’s stock worth $129,000 after buying an additional 219 shares during the period. CMH Wealth Management LLC acquired a new stake in Edwards Lifesciences Corporation during the second quarter worth $1,761,000. Wellington Shields Capital Management LLC increased its stake in Edwards Lifesciences Corporation by 124.1% in the second quarter. Wellington Shields Capital Management LLC now owns 48,840 shares of the medical research company’s stock worth $5,775,000 after buying an additional 27,050 shares during the period. Finally, Meag Munich Ergo Kapitalanlagegesellschaft MBH acquired a new stake in Edwards Lifesciences Corporation during the second quarter worth $7,413,000. Institutional investors own 84.67% of the company’s stock.
Edwards Lifesciences Corporation (EW) traded down 0.41% on Friday, reaching $113.11. 1,134,626 shares of the company’s stock traded hands. The firm has a market capitalization of $23.88 billion, a P/E ratio of 34.31 and a beta of 0.63. Edwards Lifesciences Corporation has a 52 week low of $81.12 and a 52 week high of $121.75. The stock has a 50-day moving average of $116.42 and a 200 day moving average of $106.02.
Edwards Lifesciences Corporation (NYSE:EW) last posted its earnings results on Wednesday, July 26th. The medical research company reported $1.08 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.88 by $0.20. Edwards Lifesciences Corporation had a return on equity of 27.17% and a net margin of 22.16%. The firm had revenue of $842 million during the quarter, compared to analyst estimates of $839.16 million. During the same period in the previous year, the company earned $0.76 EPS. The company’s revenue for the quarter was up 10.9% on a year-over-year basis. On average, equities analysts expect that Edwards Lifesciences Corporation will post $3.78 EPS for the current fiscal year.
Several equities analysts recently commented on EW shares. Vetr downgraded shares of Edwards Lifesciences Corporation from a “strong-buy” rating to a “buy” rating and set a $124.67 price target on the stock. in a report on Monday, May 15th. Zacks Investment Research upgraded shares of Edwards Lifesciences Corporation from a “hold” rating to a “buy” rating and set a $125.00 target price on the stock in a research note on Monday, May 22nd. Goldman Sachs Group, Inc. (The) started coverage on shares of Edwards Lifesciences Corporation in a research note on Tuesday, May 16th. They issued a “conviction-buy” rating and a $138.00 target price on the stock. Canaccord Genuity reaffirmed a “buy” rating and issued a $150.00 price target on shares of Edwards Lifesciences Corporation in a research report on Wednesday, June 28th. Finally, Barclays PLC upped their price target on shares of Edwards Lifesciences Corporation from $108.00 to $120.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 27th. Five research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $121.13.
In other news, VP Patrick B. Verguet sold 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 31st. The stock was sold at an average price of $114.88, for a total transaction of $1,148,800.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP Donald E. Bobo, Jr. sold 5,300 shares of the business’s stock in a transaction that occurred on Friday, July 28th. The shares were sold at an average price of $114.68, for a total value of $607,804.00. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 149,281 shares of company stock worth $17,331,446. Company insiders own 2.13% of the company’s stock.
About Edwards Lifesciences Corporation
Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.
Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.